Pro/Ala/Ser (PAS) peptides as an alternative to polyethylene glycol (PEG) for the surface shielding of lipid nanoparticles (LNPs) carrying therapeutic mRNA

Abstract Lipid nanoparticles (LNPs), comprising a mixture of cationic lipids, neutral phospholipids, cholesterol and, in particular, polyethylene glycol (PEG)-conjugated lipids on their surface, have emerged as a powerful technology to encapsulate and deliver protein-encoding mRNAs as modern vaccines or for therapeutic intervention. However, the common use of PEG for surface shielding of mRNA-LNPs has raised concerns, especially in the light of a growing prevalence of anti-PEG antibodies in the healthy population. PASylation offers a biological alternative to the chemical PEG polymer, employing recombinant or synthetic (poly)peptides made of the small natural L-amino acids Pro, Ala and Ser which, in contrast to PEG, are biodegradable. PAS sequences are conformationally disordered, fully uncharged but strongly solvated and, thus, closely match the biophysical properties of PEG chains. Based on this notion, we synthesized a novel PASylated lipid, Pga-PAS 40 -ditetradecylamine (PAS-DTA), by replacing the PEG moiety in a clinically approved PEG-lipid (ALC-0159) with a 40mer PAS peptide N-terminally protected with pyroglutamate (Pga). mRNA-LNPs were formulated with this PASylated lipid, adopting a published procedure for conventional LNPs, and their properties were compared with those prepared using common PEG-lipids. To this end, we designed template DNAs for the in vitro transcription (IVT) of mRNA encoding a PASylated murine interferon alpha-11 (mIFNα11) which, when systemically applied, is effective against hepatitis B infection of transgenic mice. mRNA-LNPs formulated with PASylated or PEGylated lipids showed practically identical RNA-encapsulation efficiencies (~ 50%), hydrodynamic diameters (85–120 nm) as well as Zeta potentials (− 4 to − 13 mV). In addition, cultured HepG2 and HEK293E cells transfected with the PASylated mRNA-LNPs encoding either enhanced green fluorescent protein (eGFP) or PAS 200 -mIFNα11 showed robust expression of both recombinant proteins. Furthermore, in a side-by-side experiment with HepG2 cells transfected with mRNA-LNPs that were prepared using PAS-DTA or two different PEG-lipids, comparable or slightly higher amounts of secreted PAS 200 -mIFNα11 were detected in the culture supernatant both by western blotting and ELISA. Taken together, our in vitro data indicate that PAS-lipids offer a viable alternative to PEG-lipids for the preparation of mRNA-LNPs, without immunochemical cross-reactivity but with potentially better tolerability for the transfected target cells.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-17
DOI
https://doi.org/10.1038/s41598-026-80364-w
Primary Topic
RNA Interference and Gene Delivery
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Pro/Ala/Ser (PAS) peptides as an alternative to polyethylene glycol (PEG) for the surface shielding of lipid nanoparticles (LNPs) carrying therapeutic mRNA

Arne Skerra, Lars Friedrich, Uli Binder, Cihan Makbul
5 links
Scientific Reports
RNA Interference and Gene Delivery
article

Pro/Ala/Ser (PAS) peptides as an alternative to polyethylene glycol (PEG) for the surface shielding of lipid nanoparticles (LNPs) carrying therapeutic mRNA

Arne Skerra, Lars Friedrich, Uli Binder, Cihan Makbul
article en

Abstract

Abstract Lipid nanoparticles (LNPs), comprising a mixture of cationic lipids, neutral phospholipids, cholesterol and, in particular, polyethylene glycol (PEG)-conjugated lipids on their surface, have emerged as a powerful technology to encapsulate and deliver protein-encoding mRNAs as modern vaccines or for therapeutic intervention. However, the common use of PEG for surface shielding of mRNA-LNPs has raised concerns, especially in the light of a growing prevalence of anti-PEG antibodies in the healthy population. PASylation offers a biological alternative to the chemical PEG polymer, employing recombinant or synthetic (poly)peptides made of the small natural L-amino acids Pro, Ala and Ser which, in contrast to PEG, are biodegradable. PAS sequences are conformationally disordered, fully uncharged but strongly solvated and, thus, closely match the biophysical properties of PEG chains. Based on this notion, we synthesized a novel PASylated lipid, Pga-PAS 40 -ditetradecylamine (PAS-DTA), by replacing the PEG moiety in a clinically approved PEG-lipid (ALC-0159) with a 40mer PAS peptide N-terminally protected with pyroglutamate (Pga). mRNA-LNPs were formulated with this PASylated lipid, adopting a published procedure for conventional LNPs, and their properties were compared with those prepared using common PEG-lipids. To this end, we designed template DNAs for the in vitro transcription (IVT) of mRNA encoding a PASylated murine interferon alpha-11 (mIFNα11) which, when systemically applied, is effective against hepatitis B infection of transgenic mice. mRNA-LNPs formulated with PASylated or PEGylated lipids showed practically identical RNA-encapsulation efficiencies (~ 50%), hydrodynamic diameters (85–120 nm) as well as Zeta potentials (− 4 to − 13 mV). In addition, cultured HepG2 and HEK293E cells transfected with the PASylated mRNA-LNPs encoding either enhanced green fluorescent protein (eGFP) or PAS 200 -mIFNα11 showed robust expression of both recombinant proteins. Furthermore, in a side-by-side experiment with HepG2 cells transfected with mRNA-LNPs that were prepared using PAS-DTA or two different PEG-lipids, comparable or slightly higher amounts of secreted PAS 200 -mIFNα11 were detected in the culture supernatant both by western blotting and ELISA. Taken together, our in vitro data indicate that PAS-lipids offer a viable alternative to PEG-lipids for the preparation of mRNA-LNPs, without immunochemical cross-reactivity but with potentially better tolerability for the transfected target cells.

Scientific ReportsVol. 16(1)
Technical University of Munich (DE)
Deutsche Forschungsgemeinschaft, Bundesministerium für Bildung und Forschung, Technische Universität München
Good health and well-being
RNA Interference and Gene Delivery
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon